Vaxcyte (PCVX) Depreciation & Amortization (CF) (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $2.9 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) changed 0.3% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $16.4 million, a 82.89% increase from a year earlier, with the FY2025 full-year figure at $16.4 million, up 134.13% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $2.9 million, down from $7.5 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for PCVX reached as high as $7.5 million in Q4 2025 and fell as low as $582000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.9 million across 5 years, with a median of $999000.0 in 2024.
• Across the five-year window, Depreciation & Amortization (CF) fell 7.4% in 2023 and surged 222.52% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $959000.0 in 2022, then slipped by 7.4% to $888000.0 in 2023, then jumped by 222.52% to $2.9 million in 2024, then soared by 161.77% to $7.5 million in 2025, then tumbled by 60.69% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $2.9 million in Q1 2026, $7.5 million in Q4 2025, and $3.1 million in Q3 2025.